费布克索斯塔特可能会降低患有痛风的患者中COVID-19感染的发生率:一项回顾性队列研究
Weijie Wang1, Shiow-Ing Wang2,3, Yang Cheng4
1State Key Clinical Specialty of Rheumatology, Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Frontiers in pharmacology
|November 14, 2025
概括
与Allopurinol相比,Febuxostat在痛风患者中显著降低了COVID-19感染和住院风险. 这种尿酸降低疗法可能会提供保护,即使对于那些患有脏问题或tophi.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 传染性疾病 传染性疾病
- 类风湿病学 类风湿病学
背景情况:
- COVID-19可能会导致功能障碍和高血压.
- 痛风是严重的COVID-19结果的一个危险因素.
- 尿酸降低疗法对痛风患者COVID-19风险的影响尚不清楚.
研究的目的:
- 为了调查Febuxostat是否减少了痛风患者的COVID-19发病率.
- 为了比较Febuxostat与Allopurinol在治疗痛风患者中控制COVID-19风险方面的疗效.
主要方法:
- 使用电子健康记录进行的回顾性队列研究 (N=663,729名痛风患者).
- 倾向性得分匹配确定了5,466名接受费布克索斯塔特治疗的患者和5,466名接受阿洛普林醇治疗的患者.
- 计算了COVID-19发病率和住院治疗的危险比率 (HR).
主要成果:
- 费布克索斯塔特显著降低了COVID-19发病率 (HR=0.878) 和住院治疗 (HR=0.874) 相比Allopurinol.
- 在男性,老年人,未接种疫苗的人以及血清尿酸<10 mg/dL的人群中,益处更为明显.
- 费布克苏斯塔特还减少了功能障碍或托菲 (HR=0.652) 的患者住院的风险.
结论:
- 在痛风患者中,使用febuxostat与COVID-19的风险较低有关.
- 在3年的随访期间,观察到Febuxostat的保护作用,包括功能障碍或托菲症患者.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Urinary Tract Calculi III: Medical Management
188
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
188
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
358
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
358
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
345
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
345
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
833
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
833
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
